Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

A technology of immunoglobulin and fusion polypeptide, which is applied in the field of chemokine-immunoglobulin fusion polypeptide, composition and its preparation and use, and can solve the problems of chronic unhealed wounds, reduce

Inactive Publication Date: 2018-06-29
JYANT TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Impaired wound healing in diabetic patients is accompanied by reduced early inflammatory cell infiltration, but persistence of neutrophils and macrophages contributes to chronic nonhealing wounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
  • Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
  • Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] Embodiment 1: Generation of plasmid expression vector

[0182] pFUSE-hIgG1-Fc1, pFUSE-hIgG2-Fc1, pFUSE-hIgG3-Fc1, and pFUSE-hIgG4-Fc1 vectors from InvivoGen (San Diego, CA) were used to generate chemokine-hIgG4-Fc1-expressing immunoglobulins using standard molecular biology methods. Expression vector of protein fusion polypeptide. Examples of such expression vectors are shown in Figures 1-10.

Embodiment 2

[0183] Example 2: Expression of Chemokine Receptors in Breast Cancer Cell Lines

[0184] Experiments were performed to compare the expression levels of CXCR7 and CXCR3 in breast cancer tissues of different stages, in non-neoplastic breast tissues. Nonneoplastic breast tissue did not express detectable levels of CXCR7. CXCR7 expression was significantly higher in advanced breast cancer tissues compared with non-neoplastic breast tissues. Both CXCR7 and CXCR3 mRNA were elevated in breast cancer cell line (MDA-MB-231 ) compared to normal breast cells (MCF-10A).

Embodiment 3

[0185] Example 3: var-CXCL11-IgG fusion polypeptide inhibits the activation of CXCR7 and CXCR3 in breast cancer cells

[0186] Using Amnis ImageStream analysis, the inventors found that CXCL11 stimulates the aggregation and rapid desensitization of CXCR3 and CXCR7, i.e., CXCL12 regulates modest CXCR7 clustering, and adrenomedullin (AM) stimulates CXCR3 and CXCR7 clustering. CXCL11-IgG fusion polypeptide abolishes CXCR3 and CXCR7, but not CXCR4, clustering and desensitization by CXCL11, CXCL12 and AM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.

Description

[0001] The present invention is a divisional application with an original application number of 201280032847.7, an application date of May 25, 2012, and the original title of the invention: chemokine-immunoglobulin fusion polypeptides, compositions and methods for their preparation and use. [0002] This application claims priority to US Provisional Patent Application 61 / 492,260, filed June 1, 2011. The entire contents of the foregoing application are incorporated herein by reference. technical field [0003] The present application generally relates to compositions that can be used to treat chemokine receptor-mediated disorders and to modulate inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. Background technique [0004] Chemokines are chemotactic cytokines with a molecular weight of 6kDa to 15kDa that are released by many various cells to attract and activate macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/63A61K38/19A61K47/68A61P35/00A61P35/02A61P29/00A61P31/00A61P37/02
CPCA61K38/00C07K2319/30C07K14/521A61P1/00A61P11/00A61P13/00A61P15/00A61P17/00A61P19/00A61P21/00A61P25/00A61P27/02A61P29/00A61P31/00A61P31/04A61P35/00A61P35/02A61P37/02A61P9/00Y02A50/30C07K16/2866
Inventor 詹姆斯·W·利拉德
Owner JYANT TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com